Vco. Njar et Amh. Brodie, Inhibitors of 17 alpha-hydroxylase/17,20-lyase (CYP17): Potential agents for the treatment of prostate cancer, CUR PHARM D, 5(3), 1999, pp. 163-180
Prostate cancer (PCa) is now the most prevalent cancer in men in the U.S.A.
and Europe. At present the major treatment options include surgical or med
ical castration. These strategies depend on the abolition of the production
of testosterone by the testes. However, as these procedures do not affect
adrenal androgen production, they are frequently combined with androgen rec
eptor antagonist to block their action.
Inhibition of the key enzyme which catalyzes the biosynthesis of androgens
from pregnane precursors, 17 alpha-hydroxylase/17,70-lyase (hereafter refer
red to as CYP17) could prevent androgen biosynthesis from both sources. Thu
s total blockade of androgen production by CYP17 inhibitors may provide eff
ective treatment of prostate cancer patients. Indeed, this strategy is now
an area of intense interest within research institutions and the pharmaceut
ical industry. This review highlights development in the design and evaluat
ion of both steroidal and non-steroidal CYP17 inhibitors since 1965. Major
emphasis is given to the potent CYP17 inhibitors and those which may show c
linical promise. The review could function as a comprehensive working refer
ence of research accomplishment in the field and what problems remain to be
tackled in the future.